Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome

Madlen Loebel1,*, Kristin Strohschein1,2,3, Carolin Giannini1, Uwe Koelsch3, Sandra Bauer1, Cornelia Doebis4, Sybill Thomas1, Nadine Unterwalder3, Volker von Baehr4, Petra Reinke5,6, Michael Knops1, Leif G. Hanitsch1, Christian Meisel1,3, Hans-Dieter Volk1,5, Carmen Scheibenbogen1,5

1 Institute for Medical Immunology, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany, 2 Julius Wolff Institute, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany, 3 Labor Berlin GmbH, Immunology Department, Charité University Medicine Berlin, Campus Virchow, Berlin, Germany, 4 Institute for Medical Diagnostics, Berlin, Germany, 5 Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité University Medicine Berlin, Germany, 6 Department Nephrology, Charité University Medicine Berlin, Germany

Abstract

Epstein-Barr virus (EBV) has long been discussed as a possible cause or trigger of Chronic Fatigue Syndrome (CFS). In a subset of patients the disease starts with infectious mononucleosis and both enhanced and diminished EBV-specific memory antibody titers have been reported. In this study, we comprehensively analyzed the EBV-specific memory B- and T-cell response in patients with CFS. While we observed no difference in viral capsid antigen (VCA)-IgG antibodies, EBV nuclear antigen (EBNA)-IgG titers were low or absent in 10% of CFS patients. Remarkably, when analyzing the EBV-specific memory B-cell reservoir in vitro a diminished or absent number of EBNA-1 and VCA-antibody secreting cells was found in up to 76% of patients. Moreover, the ex vivo EBV-induced secretion of TNF-α and IFN-γ was significantly lower in patients. Multicolor flow cytometry revealed that the frequencies of EBNA-1-specific triple TNF-α/IFN-γ/L-2 producing CD4+ and CD8+ T-cell subsets were significantly diminished whereas no difference could be detected for HCMV-specific T-cell responses. When comparing EBV load in blood immune cells, we found more frequently EBER-DNA but not BZLF-1 RNA in CFS patients compared to healthy controls suggesting more frequent latent replication. Taken together, our findings give evidence for a deficient EBV-specific B- and T-cell memory response in CFS patients and suggest an impaired ability to control early steps of EBV reactivation. In addition the diminished EBV response might be suitable to develop diagnostic marker in CFS.

Introduction

Chronic Fatigue Syndrome (CFS) is characterized by severe fatigue with typical post-exertional delay to recover from exhaustion, cognitive dysfunctions and flu-like symptoms [1, 2]. CFS is diagnosed based on clinical Center of Disease Control criteria scores known as Fukuda criteria [3] or on the Canadian Consensus Definition from 2004 [1]. Diagnosis of CFS is often restrained as many symptoms are not disease-specific and no diagnostic test could be established for CFS so far [4, 5, 6, 7].

Hallmarks of CFS are immune dysregulation and immune activation [8, 9, 10]. Diminished natural killer (NK)-cell cytotoxicity and reduced NK-cell derived perforin have been repeatedly reported for CFS patients [8], [10], [11]. Furthermore, increased frequencies of activated HLA-DR class II-positive CD8+ T cells were proposed as immunological activation markers in CFS [10], [11], [12], [13]. Straus et al. showed reduced proliferative responses of lymphocytes and reduced frequencies of CD4+ T cells [14]. Similarly Curria et al. reported diminished proliferation of T cells but enhanced frequencies of regulatory T cells [15].

Broderick and colleagues described a dysregulation of Th-17 priming by enhanced levels of IL-13, IL-2 and IL-8 but decreased levels of IL-5 and IL-23 in post-infectious CFS patients [16], [17]. Furthermore, the group of Skowera et al. reported an effector memory cell responsiveness bias towards type 2 in patients with CFS [12].

CFS onset typically goes along with a viral illness. Various viruses have been reported to trigger CFS. In 2009, it was published that the retrovirus XMRV is linked to CFS. Although this turned out to be a laboratory contamination, it called attention to this so far neglected disease [18], [19], [20], [21]. Herpes viruses as cause of CFS have been discussed for decades. However, stringent evidence for a clear association of enhanced or altered viral load and disease is still lacking [22], [23], [24], [25], [26], [27]. Further, in CFS data about altered serological responses against viruses of the herpes group are not consistent. Several groups reported more frequent detection of HHV6/7 load and elevated antibody titers [27], [26], [29], [30], [31] a finding that was not confirmed by others [32], [33]. Increased IgG to human cytomegalovirus (CMV), EBV viral capsid antigen (VCA),
HHV-6, Herpes-Simplex Virus (HSV)-1, HSV-2 and Cossackie viruses were reported in CFS in some studies [34], [35], [36], but not in others [37], [38]. Numerous studies have tried to find evidence for an association of CFS with EBV. In a subset of patients, CFS begins with infectious mononucleosis and enhanced EBV-specific antibody titers have been reported. Lerner et al. found serum IgM antibodies to EBV-VCA in CFS patients but not in controls and recently reported elevated antibodies against EBV-dUTPase and EBV-DNA polymerase in a subset of CFS patients [39], [40]. Consistent with these data, elevated titers of early antigen (EA)-IgG and antibodies to ZEBRA, a product of the immediate early EBV gene BamHI Z fragment leftward open reading frame (BZLF)-1, were detected in CFS patients [31], [41]. No differences in IgG titers against EBV-VCA, EBV nuclear antigen (EBNA)-1 and EA were reported in other studies [37], [42], [43].

The orally transmitted EBV initially targets the mucosal epithelium and remains in a life-long latency in memory B cells [44], [45], [46]. In healthy subjects the EBV genome usually remains latent in the so-called latency phase 0 and EBV replication is latent and without production of infectious virions [47], [48], [49], [50]. This latency is controlled by NK- and T-cell responses. Replication occurs in different cycles, including latency I characterized by the expression of EBNA-1, latency II characterized by latent membrane proteins (LMP-1 and LMP-2, and latency III when EBNA-2, -3 and -6 are also expressed [51], [52]. During lytic reactivation the EBV immediate-early genes BZLF-1 and BRLF-1 are expressed. These genes activate viral and cellular promoters that induce early, lytic and late viral gene expression and high amplification of the EBV genome [53]. EBER genes encode for regulatory RNAs. EBER-DNA can be used as a sensitive tool for the detection of EBV-infected cells, and the EBER-DNA copy number is related to the copy number of EBV-DNA molecules [54,55]. No clear differences in EBV-DNA levels in blood and gastro-intestinal biopsies of CFS patients could be demonstrated yet [33], [37], [42].

At the Charité, we take care of patients with CFS in our outpatient clinic for adult immunodeficiencies as a subset of our immunodeficiency clinics. Numerous studies have tried to find evidence for an association of CFS with EBV. An association of EBV with CFS has been discussed for more than a decade [47]–[49], [53]–[55]. At the Charité, we take care of patients with CFS in our outpatient clinic for adult immunodeficiencies as a subset of our immunodeficiency clinics. An association of EBV with CFS has been discussed for more than a decade [47]–[49], [53]–[55].

Materials and Methods

Ethics statement

The study was approved by the institutional ethics committee – Charité Universitätsmedizin Berlin and written informed consent was provided by all subjects. Only adults were included.

Study population and specimen collection

Patients were diagnosed with CFS according to Fukuda criteria at our outpatient clinic between 2007 and 2013 [3]. Patients with other medical or neurological diseases were excluded. Patients who had a concomitant immunoglobulin deficiency were excluded when they fulfilled the diagnostic criteria for CVID or required immunoglobulin substitution due to recurrent bacterial infections. Two consecutive cohorts of patients (Table 1) were analyzed for EBV antibodies. We excluded 1/64 seronegative patients (1.6%) and 4/61 controls (7%) from our analyses in cohort 1 and 28/411 (6.8%) patients in cohort 2. Due to similar numbers of seronegative patients and controls, the interpretation of our data is not affected. A subset of patients from cohort 1 was analyzed for B-cell memory response by ELISpot, and EBV-induced T-cell cytokines. A subset of patients from cohort 2 was analyzed for EBV viral load. Patients of both cohorts were analyzed for EBV-specific T-cell responses by flow cytometry. All subgroups of patients were randomly selected but were representative for the respective cohort 1 or 2 in age, disease score and duration.

Blood samples

Blood and serum was obtained from CFS patients and healthy subjects. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation using Ficoll Hypaque and either cryopreserved for T-cell analysis or directly used in cell culture stimulation assay for memory B-cell analysis.

Quantitative real-time PCR

Detection of EBV-DNA in PBMCs was done by nested PCR for EBER-1 with the following primers forward 5’TCC GGT GAC AAG CAG GCA AAA AG3’ at 900 nM. Detection has been performed with probe FAM-5’TGG TGA CCG TGT CTG TGG TTG TTG TGT T-3’TAMRA (Eurofins MWG Operon, Ebersberg Germany) at 5 μM. Amplification data were analyzed by an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, California, USA). Successful DNA isolation was verified by histone replication with the primers forward 5’-CCA GAG CGC AGC TAT CCG T-3’ at 900 nM and reverse 5’-CAG GTT TGG CAT GGA TAG CAC -3’ at 50 nM and the probe TAMRA (Eurofins MWG Operon, Ebersberg Germany) at 5 μM. For BZLF-1 the following primers forward 5’-AAATTTAAGAATCCTCGTG-TAAAACATC-3’ and reverse 5’-CGCCTCCTGTGGAAGCA-GAT-3’ at 30 pM were used. Detection has been performed with probe FAM-5’-ATAATGGAGTCAACATCCAGGCTTGGGC-3’TAMRA (Eurofins MWG Operon, Ebersberg Germany) at 10 pM. For detection of BZLF-1 RNA, isolated total RNA was reverse transcribed according to the manufacturer’s instructions (Life Technologies, Darmstadt, Germany). EBER copies/μg DNA and BZLF-1 copies/μg cDNA were calculated in accordance to

| Table 1. Patient characteristics. |
|----------------------------------|
|                                | Cohort 1 | Cohort 2 |
| **n**                           | 63       | 387      |
| Age, mean, range                | 47, 27–63| 45, 20–78|
| Women, n (%)                    | 46 (73)  | 245 (63) |
| Bell score, mean, range         | 30, 10–50| 30, 10–70|
| Disease duration in years, mean | 7.4 (1–39)| 7.4, <1–39|
| History of autoimmune disease (%)| 11.1* 93^a| 15.2/2.9/0 |
| Deficiency of IgG/IgA (%)       | 4.4/3.6/3.1| 15.2/2.9/0 |
| Deficiency of IgG (%)           | 8.18     | 16.7     |

*Hashimoto thyreoiditis (n = 6), lichen sclerosus (n = 1); ^aHashimoto thyreoiditis (n = 30), psoriasis (n = 3), colitis ulcerosa (n = 1), Morbus Bechterew (n = 2).
standard EBV-copies [60]. Results ≥35 copies/µg DNA/cDNA were regarded as positive.

Enzyme-linked immunosorbent assay (ELISA)/Enzyme immunoassay (EIA)

EBNA-IgG, VCA-IgG and VCA-IgM were detected using an immuno chemiluminescence assay (CLIA, DiaSorin, S.p.A., Saluggia, Italy) according to the manufacturer’s instructions. ELISA was used to detect EBV EBNA-l-IgG at the Labor Berlin GmbH.

ELISPOT assay

Analysis of memory B cells was adapted from Grotty et al. [61]. PBMCs were stimulated unspecifically with Pokeweed mitogen (PWM) at 10 ng/ml (Sigma Aldrich, Schnellendorf, Germany), Staphylococcus aureus Cowan at 1:10000 dilution (Merck, Darmstadt, Germany) and CpG at 6 µg/ml (InvivoGen, CA, USA) in RPMI 1640 (PAA Laboratories, Colbe, Germany) supplemented with Penicillin/Streptomycin 100× and L-Glutamine at 2 mM and 10% FCS (both Biochrom, Berlin, Germany). IFN-γ and IL-10, IL-2 and TNF-α were regarded as positive.

Cytokine analysis

Biotin at 1 µg/ml was detected using an anti-human IgG, F(ab’)2 fragment coupled to 2 mM and 10% FCS (both Biochrom, Berlin, Germany) and 0.5% gentamycin (Merck, Darmstadt, Germany). IFN-γ, IL-10, IL-2 and TNF-α were measured in cell culture supernatants with a MPXHCYTO-60K Multiplex-Immunoenzymoassay (Merk Millipore, MA, USA) on a Luminex® 200TM (Luminex, TX, USA) according to manufacturer’s instructions.

T-cell expansion

EBV-specific memory T cells were analyzed after stimulation with EBNA-1 or CMV-pp65 peptides and expansion in vitro as recently described [62]. After overnight incubation of PBMCs in IMDM (PAA Laboratories, Colbe, Germany) containing 10% AB serum (Valley Biomedical, Winchester, VA, USA) and supplemented with Penicillin/Streptomycin 100× and L-glutamine at 2 mM (both Biochrom, Berlin, Germany) at 37°C in 5% CO2, in 96-well round bottom plates at a concentration of 2×105 cells per well with 50 IU/mL rhIL-2 (Chiron-Behring, Liederbach, Germany) and anti-human IgG-Fc-fragment antibody (Jackson diluted (tebu-bio, Le-Perray-en-Yvelines, France). Plates were scanned and spots enumerated on a CTL Immunoplate reader using Immunospot Academic software (Cellular Technology Ltd, OH, USA). Frequencies were expressed as the ratio of the mean number of antigen-specific spots and mean number of total IgG spots.

Multiparameter flow cytometry

Intracellular and extracellular staining was applied for T-cell analysis after 10 days of expansion. 2×10⁶ PBMCs were restimulated with an EBNA-1 or CMV-pp65 peptide pool (JPT, Berlin, Germany) at (1 µg/mL) or DMSO (Sigma Aldrich, Schnellendorf, Germany) as negative control for 5 h. Brefeldin A (7.5 µg/mL) (Sigma Aldrich, Schnellendorf, Germany) was added after 1 h of stimulation. Live/dead cells were discriminated using an amine reactive dye (Invitrogen, Life Technologies, Darmstadt, Germany) and stained with fluorescence conjugated monoclonal antibodies against CD3, CD4, CD8, PD-1, IFN-γ, TNF-α and IL-2 (BD Biosciences, NJ, USA). Background events in DMSO controls were subtracted from events counted in response to EBNA-1 or CMV-pp65 stimulation. Data acquisition was performed on BD LSR II (Becton Dickinson, NJ, USA) and analysis was done using FlowJo software.

Statistical analysis

Statistical data analysis was done using the software SPSS Statistics 19 and GraphPad Prism 5. Nonparametric statistical methods were used. Continuous variables were expressed as median and interquartile range (IQR), if not indicated otherwise. Univariate comparisons of two independent groups were done using the Mann-Whitney-U test. For association analysis Fisher’s exact test was used. A p-value of <0.05 was considered statistically significant.

Results

A significant subset of CFS patients shows abnormal EBV serology

First, we analyzed the EBV-specific antibody response from CFS patients. We compared serum EBV-VCA-IgG, -IgM, and EBNA-IgG from patients of cohort 1 (n = 63, Table 1) and healthy controls (n = 57) (Figure 1A). While we did not observe a difference in levels of VCA-IgG, IgG antibodies against EBNA were undetectable (≥20 U/ml) in 12.7% of CFS patients in contrast to 3.5% of healthy controls (p = 0.06, Figure 1B). When excluding the values which were out of range, we obtained similar results with comparable levels for VCA-IgG and a significant difference for EBNA-IgG (p = 0.05, data not shown).

Further, elevated VCA-IgM was found more frequently in patients compared to healthy controls (17.5 vs. 3.5% p = 0.013,
Figure 1. EBNA antibody response is reduced in CFS patients. (A) Serum IgG titers were assessed for healthy controls and CFS patients by ELISA for EBV VCA-IgG (control n = 57, CFS n = 63), (B) EBNA-IgG (control n = 57, CFS n = 63), (C) EBV VCA-IgM (control n = 57, CFS n = 63), (D) CMV-IgG (control n = 32, CFS n = 41) and (E) CMV-IgM (control n = 32, CFS n = 41). Statistical analysis was performed using the two-tailed Mann-Whitney-U test and for EBNA-IgG and EBV VCA-IgM Fisher’s exact one-tailed test for association analysis with * p < 0.05.

doi:10.1371/journal.pone.0085387.g001

In a second consecutive cohort with 387 CFS patients (Table 1), EBV-specific antibodies were measured by ELISAs that determine IgG against a mixture of various EBV proteins or EBNA-1, respectively. Similarly, we observed a lack of EBNA-1-IgG in 9.8% of EBV-IgG positive patients (Figure 2A). In a randomly selected subset of 8 EBNA-1-IgG positive and 7 negative patients we further comparatively analyzed total IgG levels, frequencies of B cells, and B-cell subsets. No difference in total IgG (Figure 2B) was found in EBNA-1-IgG negative compared to EBNA-1-IgG positive CFS patients. Moreover, the absolute B-cell numbers (Figure 2C) and frequencies of memory B-cell subsets were not different among EBNA-1 negative and positive patients (Figure 2D and Figure 2E) and were within the normal range compared to the reference values of our immune diagnostic laboratory.

EBV-specific memory B cells are low or absent in most CFS patients

Serum IgG antibodies are mostly derived from long-living plasma cells, which have settled in the bone marrow, often many years before. Thus, disturbance of memory B-cells can be overlooked for long time if only IgG serum levels are analyzed. Therefore, we studied the frequencies of specific antibody-secreting cells (ASCs) derived from EBV-specific memory B cells after in vitro restimulation by activating PBMCs with a mixture of CpG, SAC, and PWM for 7 days. ASCs were analyzed in the ELISpot assay. No difference between CFS patients and healthy controls was detected for total IgG secreting memory B cells (Figure 3A). However, the CFS patients had significantly reduced frequencies of B cells producing antibodies against EBV antigen mixture (EBV-lysate). In addition, by using overlapping peptide pools, VCA-specific and EBNA-1-IgG secreting B cells were analyzed. A diminished B-cell memory response was defined by frequencies below the interquartile range of the control group. As shown in Figure 3B a diminished B-cell memory response against EBV-VCA was observed in 59% of CFS patients, and against EBV-EBNA in 76% of patients, respectively. We found no correlation between frequencies of VCA- or EBNA-specific memory B cells and levels of IgG antibodies (VCA r = 0.1242, p = 0.67 and EBNA r = 0.07913, p = 0.8). Patients analyzed for memory B cells were derived from cohort 1 and their IgG titers were comparable to the IgG titers of the whole cohort 1 (median VCA-IgG 350 vs. 450 U/ml, EBNA-IgG 100 vs. 180 U/ml, shown in Figure 1B). We determined HSV- and CMV lysate-specific ASCs in a subgroup of these patients detecting no difference between patients and controls further excluding a general B-cell defect (Figure 3C and Figure 3D). To assess whether the reduction of EBV-specific memory B cells is possibly due to the presence of suppressive T cells in culture, enriched B cells were cultivated without T cells in the presence of feeder LL8 cells. Soluble CD40 ligand together with a cytokine mix and CpG were used to induce memory B-cell differentiation. Similar numbers of EBV-specific antibody secreting B cells were detected in patients in the T-cell dependent and independent analysis (Figure 3E). Taken together, the lack or reduced level of memory B cells shows a more profound deficiency of the EBV-specific B-cell response as evident from serology.

CFS patients show diminished T-cell cytokine response to EBV

In a next series of experiments, we analyzed the EBV-specific T-cell response in patients and healthy controls. First, EBV-lysate induced production of several cytokines that were tested in whole blood, revealed a significantly reduced number of IFN-γ
responders in the patient group with 50% (n = 11/22) vs. 69% (n = 20/29) in the control group (Figure 4A). Using whole protein-spanning overlapping 15-mer peptides from EBNA-1 protein for stimulation, no patient showed a detectable IFN-γ response (Figure 4A). Similar IFN-γ levels were observed in response to the T-cell superantigen SEB in patients and controls. In addition, a significant reduction of TNF-α and a lower number of patients producing IL-2 was observed in response to EBV-lysate, while the IL-10 response was not diminished (Figure 4B).

CFS patients show reduced EBV-specific multifunctional memory T cells

To analyze the EBV-specific memory T-cell response in more detail, we stimulated PBMCs with EBNA-1 peptides and expanded them in vitro in the presence of IL-2 and IL-7 for 10 days as recently described [60]. IFN-γ+ TNF-α+ and IL-2+ producing CD3+CD4+ and CD3+CD8+ T cells were analyzed by flow cytometry. Frequencies of EBV-specific T cells were lower in CFS patients (n = 23) compared to the control group (n = 17, Figure 5A). The difference was most evident in the IFN-γ+ TNF-α+ IL-2+ triple producing - so-called multifunctional - CD4+ and CD8+ T cells. In addition, the frequencies of the IFN-γ+ TNF-α+ double producers were significantly lower in the patient group. No difference was observed for the single producers. A diminished EBV-specific T-cell response was defined by frequencies below the interquartile range of the control group in CD4+ and CD8+ triple cytokine producing T cells. Based on this definition a diminished response was detected in 48% of CFS patients for triple CD4+ T cells and in 52% of patients for triple CD8+ T cells. As control, we analyzed the T-cell response against CMV peptide pp65 in a subset of CMV-reactive subjects (Figure 5A, right panel) showing no difference among triple and double CMV-reactive T cells between patients (n = 5) and controls (n = 7). Comparing the total cell numbers of cultures stimulated with EBNA-1, no difference was observed (patients median 77%, range 44%–106% of initial cell number, controls median 93%, range 28%–148% of initial cell number). Next, we analyzed the expression of the exhaustion marker PD-1 on EBNA-1- and CMV-pp65-specific T cells but found no difference in the frequencies of PD-1 expression between patients and controls as shown for the population of the IFN-γ+ TNF-α+ double producing CD4+ and CD8+ T cells in Figure 5B (n = 8).

Evidence of enhanced latent EBV replication in CFS patients

As a measure of the EBV load, we determined EBER DNA by real-time PCR in whole blood. EBER-DNA was detectable in 21 of 290 patients (7.2%) in a low copy number (<1000 – 2.930 copies/ml). In a subset of patients and controls we comparatively analyzed EBV DNA in isolated PBMCs. EBER-DNA was detected in 21 of 290 patients (7.2%) in a low copy number (<1000 – 2.930 copies/ml). In a subset of patients and controls we comparatively analyzed EBV DNA in isolated PBMCs. EBER-DNA was
detectable in 55% of patients (n = 11/20) compared to 15% (n = 3/20) of healthy controls (p < 0.01) (Figure 6A). No EBER-DNA was detected in the plasma (data not shown). Additionally, we tested 4 EBV seronegative CFS patients and detected no EBER DNA in PBMCs (data not shown). As a marker for lytic replication we further analyzed RNA levels of the lytic protein BZLF-1 in PBMCs (n = 20) but could not detect BZLF-1 cDNA in patients or controls (Figure 6B). As positive control copies/μg cDNA of EBV cell line 293T/B95-8 were determined.

**Discussion**

For many years, researchers have suspected EBV to be involved in CFS. A hallmark of CFS is chronic activation of the immune system, which can be triggered by infectious or non-infectious agents [63], [64], [65]. Although altered EBV-specific antibody titers have been repeatedly demonstrated in CFS, no clear evidence for chronic EBV replication has been obtained so far.

To contribute to the understanding of CFS, our present study aims to further elucidate the immune response to EBV in CFS.

First of all we could confirm previous reports providing serological evidence of EBV reactivation by demonstrating elevated IgM antibodies against the late VCA antigen in a subset of patients [39], [31], [41]. Remarkably, in line with this finding we could provide evidence of enhanced viral load of EBV by detection of EBV DNA in a significantly higher proportion of patients compared to healthy controls. However, no patient showed a high viral load as seen in EBV-associated post-transplant lymphoproliferative disorder or acute infectious mononucleosis. Further, we had no evidence of lytic replication as we could neither detect EBER DNA in plasma nor BZLF-1 RNA in PBMCs. Thus, our findings suggest a higher level of latency-associated replication in CFS patients.

A key finding in our study was the lack of IgG antibodies to EBNA-1 antigen, observed in a subset of patients in 2 different cohorts. EBNA-1 is one of the few gene products expressed in type
I latency. Assessment of EBNA-IgG is used for diagnosis of EBV infection, as it is mounted rather late during primary infection and a failure to produce EBNA-IgG had been observed both in severe infectious mononucleosis and chronic active EBV disease [66], [67]. However, serum IgG levels do not reflect the number of B-cell memory cells as serum IgG is derived from long-lived plasma cells, which often have been acquired many years ago. To investigate the memory B-cell response in more detail, we analyzed the in vitro differentiated EBV-specific memory B-cell pool revealing a much more profound defect in EBV-directed B-cell response with low or undetectable EBV-specific ASCs in the majority of patients. Remarkably, memory B-cell responses not only against EBNA-1, but also against the late lytic antigen VCA were low to absent in the majority of patients despite normal IgG-VCA titers indicating a secondary exhaustion of the memory B-cell pool. Alternatively, an impaired ability to mount a sufficient number of EBV-specific memory B cells upon primary infection may be discussed. This deficiency seems to be specific for EBV as total IgG, CMV-specific antibodies and CMV- and HSV-specific B-cell memory responses were not different compared to healthy controls. Further, no differences in the amount of total IgG or B cells and memory B cells was observed between EBNA-1-IgG negative and -positive patients. The failure to detect ASCs in vitro might either be related to a loss of memory B cells or their failure to differentiate into ASCs. To exclude that T cells in CFS patients inhibit or kill in vitro differentiating EBV-memory B cells, we additionally used a T-cell independent ASCs-inducing protocol showing similar results.

In accordance with the diminished EBV-specific memory B-cell response, we could demonstrate an impaired EBV-specific T-cell response, particularly of the triple and double cytokine producers. Based on our findings we assume frequent EBV reactivation as a mechanism for the impaired EBV-specific B- and T-cell immune responses in CFS patients. An impairment of specific T-cell responses is observed in various chronic infections. In HIV and HCV infection diminished specific polyfunctional CD8\(^+\) T cells were described [68,69,70,71]. Further, selective lack of polyfunctional T cells was demonstrated in animal models of chronic SIV and Leishmanina infection accompanied by the absence of circulating antibodies [72], [73]. The persistence and continuous exposure to antigen may drive T cells into exhaustion. This process is often accompanied by the presence of high levels of IL-10 and upregulation of immune suppressor molecules [74].

Our findings in CFS have similarities to recent studies in systemic lupus erythematosus (SLE) as well, in which EBV reactivation is thought to play an important role in disease...
Figure 5. CFS patients show reduced EBV-specific memory T-cell response. (A) Comparison of cytokine producing CD4⁺ (upper panels) and CD8⁺ T cells (lower panels) of CFS patients and healthy controls after 10 days of stimulation with EBNA-1 (left panel, Control n = 17, CFS n = 23). Boolean gating strategy was applied to analyze IFN-γ/TNF-α/IL-2 triple, IFN-γ/TNF-α single cytokine producing T cells after intracellular staining of isolated PBMCs incubated with Brefeldin A for 16 h. Stimulation with CMV pp65 (right panel, Control n = 7, CFS n = 5) is shown for IFN-γ/TNF-α/IL-2 triple, and IFN-γ single cytokine producing T cells. (B) Frequencies of PD-1 expression were analyzed for IFN-γ/TNF-α double producing CD4⁺ and CD8⁺ T cells after 10 days of stimulation with EBNA-1 or pp65 (n = 8). Statistical analysis was performed using the two-tailed Mann-Whitney-U test with ** p < 0.01.

doi:10.1371/journal.pone.0085387.g005

Figure 6. Latent EBV can be detected more frequently in CFS patients. (A) EBV DNA was analyzed via nested real-time PCR in total PBMCs of 20 healthy donors and CFS patients for EBER-1. EBER-copies were calculated in accordance to Namalwa standard. (B) BZLF-1 RNA was analyzed via nested real-time PCR in total PBMCs of 20 healthy donors and CFS patients but no BZLF-1 cDNA was detected. cDNA of EBV cell line 293T/B95-8 was used as positive control. Statistical analysis was performed using the one-tailed Mann-Whitney-U test with ** p < 0.01.

doi:10.1371/journal.pone.0085387.g006
T cells were shown to have higher levels of PD-1 in SLE compared to antibodies were reported for SLE as well as for patients with our findings in CFS, increased levels of EBV/EBNA-1 directed antibodies were shown to have higher levels of PD-1 in SLE compared to healthy controls [81], a finding we did not observe in our patients. Finally, we think the altered pattern of the specific immune response to EBV may be suitable as a diagnostic marker for CFS. The most prominent finding is the very low or absent B-cell memory response to EBV in the majority of CFS compared to healthy controls. Therefore we are currently evaluating the antibody responses against a broad variety of EBV peptides from different proteins by an EBV seroarray. Further, we are evaluating fluorescence-labelled EBNA- and VCA peptides for the ex vivo quantitation of specific memory B cells by flow cytometry. Taken together, this study provides clear evidence that deficiency of EBV-specific immune response is present in CFS. As EBV is known to be controlled by cell-mediated immunity, a diminished memory T- and B-cell response may result in impaired control of EBV. EBV replication is risk factor for development of lymphomas and autoimmune diseases both occurring at enhanced frequencies in CFS patients [83,84].

Acknowledgments

This paper is dedicated to Ruediger von Baehr who passed on June 21, 2012.

Author Contributions

Conceived and designed the experiments: ML KS HDV CM. Performed the experiments: ML KS SB ST. Analyzed the data: ML KS CG SB CS. Contributed reagents/materials/analysis tools: OG UK NU LH CD Vb Vo CM PR. Wrote the paper: ML KS CS HDV.

References

1. Carruthers BM, van de Sande MI, De Meulier KL, Klimas NG, Broderick G, et al. (2011) Myalgic Encephalomyelitis/International Consensus Criteria. J Intern Med 270: 327–338.
2. Christley Y, Duffy T, Martin CR (2012) A review of the definitional criteria for chronic fatigue syndrome. J Eval Clin Pract 18: 25–31.
3. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, et al. (1994) The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121: 595–599.
4. Tanaka Y (2012) Biomarkers of stress and fatigue. Nihon Rinsho 70: 880–896.
5. Bansal AS, Bradley AS, Bishop KN, Kiani-Alikhan S, Ford B (2012) Chronic fatigue syndrome, the immune system and viral infection. Brain Behav Immun 26: 24–31.
6. Shepherd C (2002) Editorial on CFS was biased, inaccurate, and misleading. BMJ 324: 914.
7. Jason LA, Torres-Harding SR, Carrico AW, Taylor RR (2002) Symptom occurrence in persons with chronic fatigue syndrome. Biol Psychol 59: 15–27.
8. Maher KJ, Klimas NG, Fletcher MA (2005) Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol 142: 503–511.
9. Jason LA, Fricano G, Taylor RR, Halpernt, JF, Fennell PA, et al. (2000) Chronic fatigue syndrome: an examination of the phases. J Clin Psychol 56: 1497–1508.
10. Breen EW, van Driel MI, Staines DR, Ashton KJ, Ramos SB, et al. (2011) Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. J Transl Med 9: 81.
11. Fletcher MA, Zeng XR, Maher K, Levin S, Hunter B, et al. (2010) Biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase IV/CD26. PLoS One 5: e10817.
12. Skowera A, Cleare A, Blair D, Bevis L, Wessely SG, et al. (2004) High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol 135: 294–302.
13. Klimas NG, Salvato FR, Morgan R, Fletcher MA (1998) Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 26: 1403–1410.
14. Straus SE, Fritz S, Dale JK, Gould B, Strober W (1993) Lymphocyte phenotype and function in chronic fatigue syndrome: a comprehensive approach to its definition and study. J Intern Med 121: 595–599.
15. Cunha MM, Carrilho J, Massanella M, Rigaú J, Alègre J, et al. (2013) Screening NK, B- and T-cell phenotype and function in patients suffering from Chronic Fatigue Syndrome. J Transl Med. doi: 10.1186/1479-5876-11:68.
16. Broderick G, Katz BZ, Fernandes H, Fletcher MA, Klimas N, et al. (2012) Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue. J Transl Med 10: 191.
17. Broderick G, Fuite J, Kreutz A, Vernon SD, Klimas N, et al. (2010) A formal analysis of cytokine networks in chronic fatigue syndrome. Brain Behav Immun 24: 1209–1217.
18. Lombardi VC, Ruscitti FW, Das Gupta J, Ploot MA, Hagin KS, et al. (2009) Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome. Science 323: 363–369. Retraction in: Alberts B. Science 323: 2681.
19. Hohn O, Srdoucheva K, Brandt AU, Secher S, Klein S, et al. (2010) No evidence for XMRV in German CFS and MS patients with fatigue despite the ability of the virus to infect human blood cells in vitro. PLoS One 5: e15632.
20. van Kuppevelt KJ, van der Meer JW (2012) XMRV and CFS: the sad end of a story. Lancet 357: e27–28.
21. Simmons G, Glynis SA, Komaroff AL, Mikovits JA, Tohler LH, et al. (2011) Failure to confirm XMRV/MLVs in the blood of patients with chronic fatigue syndrome: a multi-laboratory study. Science 334: 814–817.
22. Komaroff AL, Cho TA (2011) Role of infection and neurologic dysfunction in chronic fatigue syndrome. Semin Neurol 31: 325–337.
23. Schuurberg A, Straus SE, Peterson P, Blumenthal S, Komaroff AL, et al. (1992) NIH conference: Chronic fatigue syndrome research. Definition and medical outcome assessment. Ann Intern Med 117: 325–331.
24. Josephs SF, Henry B, Balachandran N, Strayer D, Peterson D, et al. (1991) HHV-6 reactivation in chronic fatigue syndrome. Lancet 337: 1346–1347.
25. Secchiere P, Zella D, Crowley RG, Gallo RC, Lusso P (1995) Quantitative PCR for human herpesvirus 6 and 7. J Clin Microbiol 33: 2124–2130.
26. Pataki M, Komaroff AL, Conley E, Oyo-Amaze EA, Peter JB (1995) Prevalence of IgM antibodies to human herpesvirus 6 early antigen (p41/38) in patients with chronic fatigue syndrome. J Infect Dis 172: 1364–1367.
27. Ablashi DV, Eastman EB, Owen CB, Roman MM, Friedman J, et al. (2000) Frequent HHV-6 reactivation in multiple sclerosis (MS) and chronic fatigue syndrome (CFS) patients. J Virol 74: 179–191.
28. Chapenko S, Krumina A, Logina I, Rasa S, Chitajkovs M, et al. (2012) Association of active human herpesvirus-6 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. Adv Virol 2012: 205083.
29. Chapenko S, Krumina A, Kozireva S, Nora S, Sultanova A, et al. (2006) Activation of human herpesvirus 6 and 7 in patients with chronic fatigue syndrome. J Clin Virol 37 Suppl 1: S47–51.
30. Krueger GR, Koch B, Hoffmann A, Rojo J, Brandt ME, et al. (2001) Dynamics of chronic active herpesvirus-6 infection in patients with chronic fatigue syndrome: data acquisition from computer modeling. In Vivo 15: 240–246.
31. Sairenji T, Yamamishi K, Tachibana Y, Bertoyn G, Kurata T (1995) Antibody responses to Epstein-Barr Virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 38: 269–273.
32. Burzelo PD, Bayat A, Wang Q, Numan TB, Baranick GN, et al. (2012) No serological evidence for a role of HHV-6 infection in chronic fatigue syndrome. Am J Trans Res 4: 443–451.
33. Frémont M, Metzger K, Rady H, Hulttaert J, De Meulier K (2009) Detection of herpesviruses and parvovirus B19 in gastric and intestinal mucosa of chronic fatigue syndrome patients. In Vivo 23: 209–213.
34. Beqja SH, Lerner AM, Fitzgerald JT (2008) Immunomodulation with cytomegalovirus early antigens from gamma 41/42 genes in patients with chronic fatigue syndrome. J Transl Med 6: 7. J Clin Microbiol 40: 2124–2130.
35. Sairenji T, Yamamishi K, Tachibana Y, Bertoyn G, Kurata T (1995) Antibody responses to Epstein-Barr virus, human herpesvirus 6 and human herpesvirus 7 in patients with chronic fatigue syndrome. Intervirology 38: 269–273.
36. Manian FA (1994) Simultaneous measurement of antibodies to Epstein-Barr virus, human herpesvirus 6, herpes simplex virus 1 and 2, and human herpesvirus 6 in chronic fatigue syndrome: is there evidence of activation of a non-specific polyclonal immune response? Clin Infect Dis 19: 448–453.
37. Cameron B, Flaman L, Juwana H, Middlebrook J, Naing Z, et al. (2010) Serological and virological investigation of the role of the herpesviruses EBV, CMV and HHV-6 in post-infective fatigue syndrome. J Med Virol 82: 1684–1688.
38. Soto NE, Straus SE (2000) Chronic Fatigue Syndrome and Herpesviruses: the Fading Evidence. Herpes 7: 46–50.
39. Lerner AM, Beqaj SH, Deeter RG, Fitzgerald JT (2004) IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In Vivo 18: 101–106.

40. Lerner AM, Ariza ME, Williams M, Jason L, Beqaj S, et al. (2012) Antibody to Epstein-Barr virus deoxyuridine triphosphate nucleotidohydrolase and deoxyouridine monophosphate polymerase in a chronic fatigue syndrome subset. PLoS One 7: e47891.

41. Kawai K, Kawai A (1992) Studies on the relationship between chronic fatigue syndrome and Epstein-Barr virus in Japan. Intern Med 31: 313–318.

42. Wallace HL, 2nd, Nateleen B, Gause W, Hay J (1999) Human herpesviruses in chronic fatigue syndrome. Clin Diagn Lab Immunol 6: 216–223.

43. Whelton CL, Salti I, Moldsaks H (1992) Sleep, Epstein-Barr virus infection, musculoskeletal pain, and depressive symptoms in chronic fatigue syndrome. J Rheumatol 19: 939–943.

44. Greenman JS, Greenman D, Lemette ET, Abrams DI, Conant MA, et al. (1985) Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med 313: 1564–1571.

45. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS (1994) Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 330: 1232–1236.

46. Nilsson K, Klein G, Henle W, Henle G (1971) The establishment of lymphohistoid lines from adult and fetal human lymphoid tissue and its dependence on EBV. Int J Cancer 8: 443–450.

47. Yates J, Warren N, Kriseman D, Sugden B (1984) A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 81: 3906–3910.

48. Altmann M, Pich D, Ruiss R, Wang J, Sugden B, et al. (2006) Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A 103: 14181–14193.

49. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA (1998) EBV persistence in memory B-cells in vivo. Immunity 9: 393–404.

50. Cohen JJ (1999) The biology of Epstein-Barr virus: lessons learned from the virus and the host. Curr Opin Immunol 11: 365–370.

51. Rezk SA, Weiss LM (2007) Epstein-Barr virus-associated lymphoproliferative disorders. Hum Pathol 38: 1293–1304.

52. Klein G, Klein E, Kushuba E (2016) Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 469: 57–63.

53. Tsurumi T, Fujita M, Kudoh A (2005) Latent and lytic Epstein-Barr virus infection. Adv Cancer Res 107: 119–136.

54. Yates J, Warren N, Kriseman D, Sugden B (1984) A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 81: 3906–3910.

55. Klein G, Klein E, Kushuba E (2016) Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 469: 57–63.

56. Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS (1994) Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 330: 1232–1236.

57. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, et al. (2005) Novel method for detection of virus-specific CD4+ T-cells in untreated HIV-infected subjects. J Immunol Methods 286: 111–122.

58. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, et al. (2005) Progressive telomere shortening of Epstein-Barr virus-specific memory T-cells indicates a decreased polyfunctionality, and clonal turnover. J Exp Med 204: 2473–2485.

59. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by EBV-specific CD8+ T-cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473–2485.

60. Heule W, Heule G, Anderson J, Emerig I, Klein G, et al. (1987) Antibody responses to Epstein-Barr virus nuclear antigens defined by gene transfer. N Engl J Med 312: 570–574.

61. Altmann M, Pich D, Ruiss R, Wang J, Sugden B, et al. (2006) Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci U S A 103: 14181–14193.

62. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, et al. (2007) Superior control of HIV-1 replication by EBV-specific CD8+ T-cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204: 2473–2485.

63. Betts MR, Exley B, Price DA, Bansal A, Camacho ZT, et al. (2005) Characterization of functional and phenotypic changes in anti-Gag-vaccine-induced T-cell responses and their role in protection after HIV-1 infection. Proc Natl Acad Sci U S A 102: 4352–4357.

64. Rodríguez-Gervais IG, Righby H, Jouan L, Sauvé D, Sékaly RP, et al. (2010) Dendritic cell inhibition is connected to exhaustion of CD8+ T-cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 184: 3154–3164.

65. Radziejewska H, Bęgou CG, Fernandez ML, Workowski KA, Obiede K, et al. (2007) Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Viral 81: 2545–2553.

66. Niller HH, Wolf H, Minorovits J (2008) Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity 41: 296–309.

67. Draborg AH, Jørgensen JM, Müller H, Nielsen CT, Jacobsen S, et al. (2012) Epstein-Barr virus early antigen diffuse immunoglobulin A antibodies in systemic lupus erythematosus patients. Scand J Rheumatol 41: 280–289.

68. Nielsen N, Sauce D, Deback C, Arnaud L, Mathian A, et al. (2002) Leishmania pifanoi pathogenic: selective lack of a local cutaneous response in the absence of circulating antibody. Infect Med 70: 6607–6609.

69. McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, et al. (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med 11: 85–89.

70. Dreyfus DH (2011) Autoimmune disease: A role for new anti-viral therapies? Autoimmun Rev 11: 309–317.

71. Chang CM, Warren JL, Engels EA (2012) Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults. Cancer 118:5929–5936.

72. Ortega-Hernandez OD, Shoufey Y (2009) Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence? Scand J Immunol 91: 185–200.

73. Larsen M, Sauce D, Debacq C, Arnaud L, Mathian A, et al. (2002) Exhausted EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. J Exp Med 205: 1763–1773.